Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients

BACKGROUND AND AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has long been considered a key regulator in lipid metabolism. Its role as a potential player in immune response has recently earned much attention. However, the effects of evolocumab, an approved PCSK9 monoclonal antibody, on...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Ziwei, Yu, Zaixin, Liang, Benhui, Zhao, Lin, Li, Jianghua, Pang, Xinli, Liu, Qiyun, Xu, Cong, Dong, Shaohong, Sun, Xin, Li, Tangzhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397913/
https://www.ncbi.nlm.nih.gov/pubmed/36017088
http://dx.doi.org/10.3389/fcvm.2022.939791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397913/
https://www.ncbi.nlm.nih.gov/pubmed/36017088
http://dx.doi.org/10.3389/fcvm.2022.939791

Ejemplares similares